In the Policy and Campaigns team at Breast Cancer Now we're still looking to speak to people with experience of olaparib (also known as Lynparza) for their primary breast cancer to inform our work to help ensure this treatment can be made available to eligible patients on the NHS.
I work in the Policy and Campaigns team at Breast Cancer Now.
As you may be aware the National Institute for Health and Care Excellence (NICE) is currently assessing olaparib (also known as Lynparza) to see whether it can be made available on the NHS for the adjuvant treatment of high-risk, HER2-negative, BRCA positive primary breast cancer.
We're currently gathering evidence and insights to help inform our response to the assessment of this treatment. As part of this we would like to hear from anybody who has received the treatment, whether through the clinical trial or an early access scheme.